Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.61 ^USD	-5.00%		-4.24%	+18.75%

May. 02	Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate Platform	CI
Apr. 04	UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating	MT

Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 15, 2023 at 04:11 pm EDT

Kodiak Sciences Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 70.78 million compared to USD 95.71 million a year ago. Basic loss per share from continuing operations was USD 1.35 compared to USD 1.83 a year ago.

Latest news about Kodiak Sciences Inc.

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate Platform	May. 02	CI
UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating	Apr. 04	MT
Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating	Apr. 01	MT
Transcript : Kodiak Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28	MT
Sector Update: Health Care	Mar. 28	MT
Top Midday Decliners	Mar. 28	MT
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss	Mar. 28	MT
Kodiak Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Transcript : Kodiak Sciences Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	Jan. 10
UBS Trims Kodiak Sciences Price Target to $3 From $4, Maintains Neutral Rating	Dec. 21	MT
Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
Kodiak Sciences' Q3 Loss Narrows	Nov. 14	MT
Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Nov. 06	MT
Sector Update: Health Care	Nov. 06	MT
Kodiak Sciences Share Fall; Company to Resume Tarcocimab Tedromer Eye Drug Development Program	Nov. 06	MT
Kodiak Sciences Inc. Announces Phase 3 Glow Superiority Study Evaluating Tarcocimab Tedromer 5 Mg in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy	Nov. 06	CI
Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting	Nov. 01	CI
European Midday Briefing : Geopolitical Risks Continue to Drag on Stocks	23-10-17	DJ
Lonza Shares Drop After Warning of 2024 Profitability Shortfall	23-10-17	DJ
Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue	23-10-17	DJ

Chart Kodiak Sciences Inc.

Duration

Period

More charts

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.61 USD

Average target price

4.25 USD

Spread / Average Target

+17.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KODIAK SCIENCES INC.	+18.75%	189M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs